Sustaining the benefits of intravenous ketamine with behavioural activation therapy for depression: A case series
Background: Despite advances in treatments for depression, approximately one third of patients do not benefit from available therapies. Intravenous ketamine is a novel intervention that can yield rapid yet transient antidepressant effects. Behavioural activation (BA) therapy for depression has been...
Main Authors: | Jennifer L. Phillips, Pierre Blier, Jeanne Talbot |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Journal of Affective Disorders Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266691532300152X |
Similar Items
-
Biweekly vs Triweekly low dose intravenous ketamine acute series for severe major depression: A case report
by: Hernandorena Carolina, et al.
Published: (2023-12-01) -
Safety of Repeated Administration of Parenteral Ketamine for Depression
by: David Feifel, et al.
Published: (2020-07-01) -
Intravenous ketamine therapy in a patient with a treatment-resistant major depression
by: M Liebrenz, et al.
Published: (2007-04-01) -
Ketamine: A New Antidepressant?
by: Feride Karacaer
Published: (2015-03-01) -
Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression
by: Aleksander Kwaśny, et al.
Published: (2024-02-01)